for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zhejiang Hisun Pharmaceutical Co., Ltd.

600267.SS

Latest Trade

14.74CNY

Change

-0.07(-0.47%)

Volume

4,703,047

Today's Range

14.61

 - 

14.87

52 Week Range

12.48

 - 

21.97

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
14.81
Open
14.81
Volume
4,703,047
3M AVG Volume
166.62
Today's High
14.87
Today's Low
14.61
52 Week High
21.97
52 Week Low
12.48
Shares Out (MIL)
1,168.84
Market Cap (MIL)
17,310.57
Forward P/E
--
Dividend (Yield %)
0.34

Next Event

Q1 2021 Zhejiang Hisun Pharmaceutical Co Ltd Earnings Release

Latest Developments

More

Zhejiang Hisun Pharmaceutical's 2020 Net Profit Up 348.3% Y/Y

Zhejiang Hisun Pharma Gets Regulatory Approval For Asset Acquisition, Share Trade To Resume

Zhejiang Hisun Pharma's Trading In Shares To Halt Pending Regulatory Review Of Asset Acquisition

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zhejiang Hisun Pharmaceutical Co., Ltd.

Zhejiang Hisun Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, manufacture and distribution of specialty bulk pharmaceutical chemicals and preparation products. The Company's bulk pharmaceutical chemicals mainly include antineoplastic drugs, cardiovascular drugs, anti-infection drugs, endocrine control drugs, anthelmintic, as well as animal remedies, among others. The Company is also engaged in the sales of drugs manufactured by other companies. The Company distributes its products in domestic markets and to overseas markets.

Industry

Major Drugs

Contact Info

No. 46, Waisha Road, Jiaojiang District

TAIZHOU, ZHJ

318000

China

+86.576.88827809

http://www.hisunpharm.com

Executive Leadership

Guoping Jiang

Chairman of the Board, Acting President

Xiaohua Chen

Vice Chairman of the Board

Zhenying Zhang

Chief Financial Officer

Haibin Wang

Senior Vice President, Director

Shihong Cai

Vice President, Director

Key Stats

Price To Earnings (TTM)
34.28
Price To Sales (TTM)
1.52
Price To Book (MRQ)
2.14
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
125.90
LT Debt To Equity (MRQ)
16.29
Return on Investment (TTM)
7.66
Return on Equity (TTM)
3.42

Latest News

Latest News

BRIEF-Zhejiang Hisun Pharmaceutical's 9-Mth Net Profit Down 72.7% Y/Y

* SAYS 9-MONTH NET PROFIT DOWN 72.7% Y/Y Source text in Chinese: https://bit.ly/35FzsvZ Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Zhejiang Hisun Pharmaceutical Plans To Issue 2 Bln Yuan Worth Of Bonds

* SAYS IT PLANS TO ISSUE UP TO 2.0 BILLION YUAN ($288.85 million) WORTH OF BONDS Source text in Chinese: https://bit.ly/2TLXz6b Further company coverage: ($1 = 6.9241 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Zhejiang Hisun Pharmaceutical says receives approval to start selling coronavirus treatment - company filing

* RECEIVES APPROVAL TO START SELLING FAVIPIRAVIR AS POTENTIAL TREATMENT FOR NOVEL CORONAVIRUS - COMPANY FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up